Cardioprotective Actions of Hydrogen Sulfide
硫化氢的心脏保护作用
基本信息
- 批准号:8399050
- 负责人:
- 金额:$ 8.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-01-01 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute myocardial infarctionAddressAdhesionsAffectAntioxidantsApoptosisApoptoticAttenuatedBiologicalBiological AvailabilityBiological ModelsCardiacCardiac MyocytesCardiovascular DiseasesCardiovascular systemCell DeathCessation of lifeChronicComplexCystathionineDataDevelopmentEnzymesExhibitsExperimental ModelsExposure toFoundationsFunctional disorderGene TargetingGeneticHealthHealthcareHeartHeat shock proteinsHeat-Shock Proteins 70Heat-Shock Proteins 90HomeostasisHydrogen SulfideIn VitroInflammationInjuryLeft Ventricular FunctionLeukocytesLyaseMaintenanceMediatingMitochondriaMolecularMusMyocardialMyocardial InfarctionMyocardial IschemiaMyocardial Ischemic PreconditioningMyocardiumNuclear TranslocationOxidative StressPathway interactionsPatientsPhysiologicalPlayPotassium ChannelProtein IsoformsRegulationReperfusion InjuryReperfusion TherapyRespirationRoleSeriesSeveritiesSignal PathwaySignal TransductionSignaling MoleculeTherapeutic AgentsThioredoxinThioredoxin-2TimeUnited Statesclinically relevantextracellularin vivomyocardial infarct sizingnovelnovel therapeuticsoverexpressionpreconditioningresearch studytranscription factor
项目摘要
DESCRIPTION (provided by applicant): Hydrogen sulfide (H2S) has recently been identified as a physiologically important endogenous gaseous signaling molecule with a diverse array of biological activities. H2S is produced in micromolar quantities by two endogenous enzymes, cystathionine 3lyase (CGL) and cystathionine 2 synthase (CBS) and is critical for the maintenance of cardiovascular homeostasis. H2S attenuates leukocyte adhesion, modulates mitochondrial respiration, and inhibits both apoptosis, and oxidative stress. These physiological actions are ideal for the treatment of myocardial ischemia-reperfusion (MI-R) injury. Preliminary data clearly demonstrate that physiological levels of H2S significantly ameliorate MI-R injury and preserve left ventricular function. Preliminary data also indicate that H2S therapy triggers both "early" and "late" myocardial preconditioning. We also demonstrate that mice with cardiac-restricted CGL overexpression exhibit significantly increased myocardial H2S bioavailability and protection against myocardial I-R injury. The central hypothesis for the proposed studies is that H2S triggers a cardioprotective signaling cascade that confers robust cardioprotection in the setting of MI-R injury. The proposed studies will evaluate the various cardioprotective signals induced by H2S therapy during both "acute" and "chronic" pharmacological preconditioning as well as the during acute H2S therapy at the time of reperfusion. Specific Aim 1: To investigate the contribution of ATP sensitive K+ channels (KATP channels) in H2S- mediated cardioprotection against myocardial ischemia-reperfusion injury. In vitro studies will evaluate the effects of H2S on KATP channel activation and mitochondrial function. In vivo Studies will be performed using gene-targeted mice with cardiac myocyte deletion of KATP (Sur 1, Kir 6.1, and Kir 6.2 subunits) treated with H2S and subjected to MI-R. Specific Aim 2: To investigate the role of antioxidants in H2S-mediated cardioprotection. Studies will evaluate the acute and chronic effects of H2S on Nrf-2 activation and oxidative stress during MI-R. Studies will also investigate the effects of H2S on the induction of antioxidant signaling pathways in the myocardium prior to MI-R. Specific Aim 3: To investigate the role of the RISK pathway in H2S-mediated cardioprotection. Studies will investigate the effects of H2S on RISK pathway (PI3K, Akt, PKC5, and Erk 1/2) activation, downstream anti-apoptotic signaling, MPTP opening, and myocardial cell death following MI-R. The proposed studies will significantly extend our current understanding of the molecular and cellular pathophysiology of MI-R injury and provide the foundation for the development of H2S therapy for the treatment of acute myocardial infarction.
描述(申请人提供):硫化氢(H_2S)最近被鉴定为一种生理上重要的内源性气体信号分子,具有多种生物学活性。硫化氢是由两种内源性酶--胱硫醚3裂解酶(CGL)和胱硫醚2合成酶(CBS)以微摩尔量产生的,对维持心血管内环境的稳定至关重要。硫化氢可减轻白细胞黏附,调节线粒体呼吸,抑制细胞凋亡和氧化应激。这些生理作用是治疗心肌缺血再灌注损伤的理想方法。初步数据清楚地表明,生理水平的硫化氢显著改善了MI-R损伤并保护了左心功能。初步数据还表明,硫化氢治疗可触发“早期”和“晚期”心肌预适应。我们还证明,心脏限制性CGL过表达的小鼠表现出显著增加的心肌硫化氢生物利用度和对心肌I-R损伤的保护作用。建议研究的中心假设是,硫化氢触发心脏保护信号级联,在MI-R损伤的背景下提供强大的心脏保护。这项拟议的研究将评估在“急性”和“慢性”药物预适应期间以及在再灌流时的急性硫化氢治疗期间,硫化氢治疗所诱导的各种心脏保护信号。具体目的1:探讨三磷酸腺苷敏感钾通道(KATP通道)在硫化氢介导的抗心肌缺血再灌注损伤中的作用。体外研究将评估硫化氢对KATP通道激活和线粒体功能的影响。体内研究将使用心肌细胞KATP(SuR 1,KIR 6.1和KIR 6.2亚基)缺失的基因靶向小鼠,经硫化氢处理和MI-R处理后进行。具体目的2:探讨抗氧化剂在硫化氢介导的心脏保护中的作用。研究将评估在MI-R期间硫化氢对NRF-2激活和氧化应激的急性和慢性影响。研究还将探讨硫化氢对MI-R前心肌中抗氧化剂信号通路的诱导作用。具体目的3:探讨风险通路在硫化氢介导的心脏保护中的作用。研究将探讨硫化氢对MI-R后风险通路(PI3K、Akt、PKC5和ERK1/2)激活、下游抗凋亡信号、MPTP开放和心肌细胞死亡的影响。这些研究将极大地扩展我们目前对MI-R损伤的分子和细胞病理生理学的认识,并为发展硫化氢治疗急性心肌梗死提供基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID JOSEPH LEFER其他文献
DAVID JOSEPH LEFER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID JOSEPH LEFER', 18)}}的其他基金
Endogenous Hydrogen Sulfide Enzymes in Heart Failure
心力衰竭中的内源性硫化氢酶
- 批准号:
10077584 - 财政年份:2019
- 资助金额:
$ 8.06万 - 项目类别:
Novel Mitochondrial DNA Repair Enzyme for Heart Failure
治疗心力衰竭的新型线粒体 DNA 修复酶
- 批准号:
9408031 - 财政年份:2017
- 资助金额:
$ 8.06万 - 项目类别:
Novel antifibrotic small molecules for the treatment of heart failure
用于治疗心力衰竭的新型抗纤维化小分子
- 批准号:
9142025 - 财政年份:2016
- 资助金额:
$ 8.06万 - 项目类别:
Novel Sulfide Releasing Agents for Ischemic Injury
用于缺血性损伤的新型硫化物释放剂
- 批准号:
8629076 - 财政年份:2014
- 资助金额:
$ 8.06万 - 项目类别:
Novel Sulfide Releasing Agents for Ischemic Injury
用于缺血性损伤的新型硫化物释放剂
- 批准号:
8889814 - 财政年份:2014
- 资助金额:
$ 8.06万 - 项目类别:
相似海外基金
Non-invasive coronary thrombus imaging to define the cause of acute myocardial infarction
无创冠状动脉血栓显像可明确急性心肌梗塞的病因
- 批准号:
MR/Y009770/1 - 财政年份:2023
- 资助金额:
$ 8.06万 - 项目类别:
Fellowship
Impact of COVID-19 pandemic on pathophysiology of acute myocardial infarction and emergency cardiovascular care system
COVID-19大流行对急性心肌梗死病理生理学和心血管急诊系统的影响
- 批准号:
23K15160 - 财政年份:2023
- 资助金额:
$ 8.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Extreme Heat and Acute Myocardial Infarction: Effect Modifications by Sex, Medical History, and Air Pollution
酷热和急性心肌梗塞:性别、病史和空气污染的影响
- 批准号:
10709134 - 财政年份:2023
- 资助金额:
$ 8.06万 - 项目类别:
Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction
开发血液中的多 RNA 特征以进行快速诊断测试,以强有力地区分急性心肌梗死患者
- 批准号:
10603548 - 财政年份:2023
- 资助金额:
$ 8.06万 - 项目类别:
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10576349 - 财政年份:2022
- 资助金额:
$ 8.06万 - 项目类别:
Establishment of the emergency transport decision making program for patients with acute myocardial infarction using artificial intelligence (AI)
利用人工智能(AI)建立急性心肌梗死患者紧急转运决策方案
- 批准号:
22K09185 - 财政年份:2022
- 资助金额:
$ 8.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of effect of intracoronary supersaturated oxygen therapy on inhibition of no reflow phenomenon in acute myocardial infarction
冠状动脉内过饱和氧治疗抑制急性心肌梗死无复流现象的效果评价
- 批准号:
22K08135 - 财政年份:2022
- 资助金额:
$ 8.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developing Federated Learning Strategies for Disease Surveillance Using Cross-Jurisdiction Electronic Medical Records without Data Sharing: With Applications to Acute Myocardial Infarction, Hypertension, and Sepsis Detection
使用跨辖区电子病历(无需数据共享)开发疾病监测联合学习策略:在急性心肌梗塞、高血压和脓毒症检测中的应用
- 批准号:
468573 - 财政年份:2022
- 资助金额:
$ 8.06万 - 项目类别:
Operating Grants
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10339915 - 财政年份:2022
- 资助金额:
$ 8.06万 - 项目类别:
The Personalising Acute Myocardial Infarction Care to improve Outcomes (PAMICO Project)
个性化急性心肌梗死护理以改善结果(PAMICO 项目)
- 批准号:
nhmrc : 2005797 - 财政年份:2021
- 资助金额:
$ 8.06万 - 项目类别:
Partnership Projects